- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information on use in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Prevention of endometrial hyperplasia in oestrogen treatment for puberty induction or growth inhibition |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Caution is needed in acute kidney impairment, as medroxyprogesterone may cause moderate fluid retention.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Estren derivatives | ||
|---|---|---|
| G03DC03 | ||
| G03DC02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Noordam C et al,, Werkboek Kinderendocrinologie, digitale publicatie op www.nvk.nl (alleen leden), 2010
- NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 20 Dec 2021
- Pozo J., Ascertainment and treatment of delayed puberty., Horm Res, 2003, 60 Suppl 3:, 35-48
- Normann EK., Height reduction in 539 tall girls treated with three different dosages of ethinyloestradiol., Arch Dis Child., 1991, 66(11), 1275-8
- Grüters A., Effect of different oestrogen doses on final height reduction in girls with constitutional tall stature., Eur J Pediatr., 1989, 149(1), 11-3
- Drop SL, Sex steroid treatment of constitutionally tall stature, Endocr Rev., 1998, 19(5), 540-58
- Matthews D., Hormone supplementation for pubertal induction in girls., Arch Dis Child, 2017, 102(10), 975-80
- de Waal WJ., [Hormonal therapy of constitutionally tall children], Ned Tijdschr Geneeskd, 1998, 142(13), 693-7
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
